Pharmacokinetic and Safety Assessments of Concurrent Administration of Risperidone and Donepezil

Treatment of Alzheimer's disease sometimes uses combinations of drugs because dementia is frequently associated with behavioral symptoms. Risperidone and donepezil are both metabolized through cytochrome P450 2D6 and 3A4, raising the possibility of drug interactions with combination therapy. Th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical pharmacology 2003-02, Vol.43 (2), p.180-186
Hauptverfasser: Zhao, Qinying, Xie, Charles, Pesco-Koplowitz, Luana, Jia, Xinwei, Parier, Jean-Loup
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 186
container_issue 2
container_start_page 180
container_title Journal of clinical pharmacology
container_volume 43
creator Zhao, Qinying
Xie, Charles
Pesco-Koplowitz, Luana
Jia, Xinwei
Parier, Jean-Loup
description Treatment of Alzheimer's disease sometimes uses combinations of drugs because dementia is frequently associated with behavioral symptoms. Risperidone and donepezil are both metabolized through cytochrome P450 2D6 and 3A4, raising the possibility of drug interactions with combination therapy. The objective of this study was to determine whether significant drug interactions occur with concomitant administration of donepezil and risperidone. In an open‐label, three‐way crossover study, 24 healthy men were randomly assigned to receive 0.5 mg of risperidone twice daily, 5 mg of donepezil once daily, or both drugs for 14 consecutive days, followed by a 21‐day washout period. The treatment ratios of AUC and associated 90% confidence intervals (CIs) for risperidone active moiety, defined as risperidone plus 9‐hydroxyrisperidone (ratio = 110.2%; 90% CI = 103.7–117.2), and for donepezil (ratio = 97.1%; 90% CI = 90.0–103.6) were within the 80% to 125% of bioequivalence range. The treatment ratios of Cmax and associated 90% CIs for risperidone active moiety (ratio = 114.6%; 90% CI = 107.0–122.8) and for donepezil (ratio = 96.1%; 90% CI = 90.0–102.6) were also within the bioequivalence range. Therefore, no significant pharmacokinetic differences occurred in either risperidone active moiety or donepezil when given alone or in combination. Adverse events (predominantly headache, nervousness, and somnolence) were minor and comparable for all treatment groups. The results indicate that no clinically meaningful drug interactions occurred between risperidone 1 mg daily and donepezil 5 mg daily at steady state, and therefore no dosage adjustment is required when both drugs are combined with the dosage regimen studied. Additional investigations are warranted to determine the potential for interactions in elderly patients with dementia who may eliminate risperidone and donepezil more slowly and thus be more vulnerable to clinical drug interactions than the young healthy subjects examined in this study.
doi_str_mv 10.1177/0091270002239827
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21425426</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21425426</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5781-a4b158f95f83f85a2487ce2c3b7745499f73215283bb994eb1fa360683c9c34c3</originalsourceid><addsrcrecordid>eNqFkUtv1DAUhSMEokNhzwpFSGUX8PuxnA7QgkqpeKhL43hsjTuJPdiJyvDrcZiISt2w8Ev3O-deHVfVcwheQ8j5GwAkRBwAgBCWAvEH1QJSihrCAHlYLaZyM9WPqic53wAAGaHwcXUEEYOMcbioflxtdOq1iVsf7OBNrcO6_qqdHfb1Mmebc2_DkOvo6lUMZkypPOvluvfB5yHpwccwFb_4vLPJr2Owfy3elsvO_vbd0-qR0122z-bzuPr-_t231Xlz8fnsw2p50RjKBWw0aSEVTlInsBNUIyK4scjglnNCiZSOYwQpErhtpSS2hU5jBpjARhpMDD6uXh18dyn-HG0eVO-zsV2ng41jVggSRAliBXx5D7yJYwplNoUwlUQwAQoEDpBJMedkndol3-u0VxCoKXp1P_oieTH7jm1v13eCOesCnMyAzkZ3LulgfL7jCOWcEVI4cuBuYzfYlLfdeGuT2ljdDZvSFwBS-jYIAAzKBpqy4GRPZ5nv7P6_86qPq6tzylHRNQdd-U_7659Op61iHHOqri_PFLiWp584OVWX-A_1fbfs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>235948680</pqid></control><display><type>article</type><title>Pharmacokinetic and Safety Assessments of Concurrent Administration of Risperidone and Donepezil</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Zhao, Qinying ; Xie, Charles ; Pesco-Koplowitz, Luana ; Jia, Xinwei ; Parier, Jean-Loup</creator><creatorcontrib>Zhao, Qinying ; Xie, Charles ; Pesco-Koplowitz, Luana ; Jia, Xinwei ; Parier, Jean-Loup</creatorcontrib><description>Treatment of Alzheimer's disease sometimes uses combinations of drugs because dementia is frequently associated with behavioral symptoms. Risperidone and donepezil are both metabolized through cytochrome P450 2D6 and 3A4, raising the possibility of drug interactions with combination therapy. The objective of this study was to determine whether significant drug interactions occur with concomitant administration of donepezil and risperidone. In an open‐label, three‐way crossover study, 24 healthy men were randomly assigned to receive 0.5 mg of risperidone twice daily, 5 mg of donepezil once daily, or both drugs for 14 consecutive days, followed by a 21‐day washout period. The treatment ratios of AUC and associated 90% confidence intervals (CIs) for risperidone active moiety, defined as risperidone plus 9‐hydroxyrisperidone (ratio = 110.2%; 90% CI = 103.7–117.2), and for donepezil (ratio = 97.1%; 90% CI = 90.0–103.6) were within the 80% to 125% of bioequivalence range. The treatment ratios of Cmax and associated 90% CIs for risperidone active moiety (ratio = 114.6%; 90% CI = 107.0–122.8) and for donepezil (ratio = 96.1%; 90% CI = 90.0–102.6) were also within the bioequivalence range. Therefore, no significant pharmacokinetic differences occurred in either risperidone active moiety or donepezil when given alone or in combination. Adverse events (predominantly headache, nervousness, and somnolence) were minor and comparable for all treatment groups. The results indicate that no clinically meaningful drug interactions occurred between risperidone 1 mg daily and donepezil 5 mg daily at steady state, and therefore no dosage adjustment is required when both drugs are combined with the dosage regimen studied. Additional investigations are warranted to determine the potential for interactions in elderly patients with dementia who may eliminate risperidone and donepezil more slowly and thus be more vulnerable to clinical drug interactions than the young healthy subjects examined in this study.</description><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1177/0091270002239827</identifier><identifier>PMID: 12616671</identifier><identifier>CODEN: JCPCBR</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Area Under Curve ; Biological and medical sciences ; Biological Availability ; Cross-Over Studies ; Donepezil ; Drug Interactions ; Humans ; Indans - adverse effects ; Indans - cerebrospinal fluid ; Indans - pharmacokinetics ; Male ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Piperidines - adverse effects ; Piperidines - cerebrospinal fluid ; Piperidines - pharmacokinetics ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Risperidone - adverse effects ; Risperidone - blood ; Risperidone - pharmacokinetics</subject><ispartof>Journal of clinical pharmacology, 2003-02, Vol.43 (2), p.180-186</ispartof><rights>2003 American College of Clinical Pharmacology</rights><rights>2003 SAGE Publications</rights><rights>2003 INIST-CNRS</rights><rights>Copyright SAGE PUBLICATIONS, INC. Feb 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5781-a4b158f95f83f85a2487ce2c3b7745499f73215283bb994eb1fa360683c9c34c3</citedby><cites>FETCH-LOGICAL-c5781-a4b158f95f83f85a2487ce2c3b7745499f73215283bb994eb1fa360683c9c34c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1177%2F0091270002239827$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1177%2F0091270002239827$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14577644$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12616671$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhao, Qinying</creatorcontrib><creatorcontrib>Xie, Charles</creatorcontrib><creatorcontrib>Pesco-Koplowitz, Luana</creatorcontrib><creatorcontrib>Jia, Xinwei</creatorcontrib><creatorcontrib>Parier, Jean-Loup</creatorcontrib><title>Pharmacokinetic and Safety Assessments of Concurrent Administration of Risperidone and Donepezil</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><description>Treatment of Alzheimer's disease sometimes uses combinations of drugs because dementia is frequently associated with behavioral symptoms. Risperidone and donepezil are both metabolized through cytochrome P450 2D6 and 3A4, raising the possibility of drug interactions with combination therapy. The objective of this study was to determine whether significant drug interactions occur with concomitant administration of donepezil and risperidone. In an open‐label, three‐way crossover study, 24 healthy men were randomly assigned to receive 0.5 mg of risperidone twice daily, 5 mg of donepezil once daily, or both drugs for 14 consecutive days, followed by a 21‐day washout period. The treatment ratios of AUC and associated 90% confidence intervals (CIs) for risperidone active moiety, defined as risperidone plus 9‐hydroxyrisperidone (ratio = 110.2%; 90% CI = 103.7–117.2), and for donepezil (ratio = 97.1%; 90% CI = 90.0–103.6) were within the 80% to 125% of bioequivalence range. The treatment ratios of Cmax and associated 90% CIs for risperidone active moiety (ratio = 114.6%; 90% CI = 107.0–122.8) and for donepezil (ratio = 96.1%; 90% CI = 90.0–102.6) were also within the bioequivalence range. Therefore, no significant pharmacokinetic differences occurred in either risperidone active moiety or donepezil when given alone or in combination. Adverse events (predominantly headache, nervousness, and somnolence) were minor and comparable for all treatment groups. The results indicate that no clinically meaningful drug interactions occurred between risperidone 1 mg daily and donepezil 5 mg daily at steady state, and therefore no dosage adjustment is required when both drugs are combined with the dosage regimen studied. Additional investigations are warranted to determine the potential for interactions in elderly patients with dementia who may eliminate risperidone and donepezil more slowly and thus be more vulnerable to clinical drug interactions than the young healthy subjects examined in this study.</description><subject>Adult</subject><subject>Area Under Curve</subject><subject>Biological and medical sciences</subject><subject>Biological Availability</subject><subject>Cross-Over Studies</subject><subject>Donepezil</subject><subject>Drug Interactions</subject><subject>Humans</subject><subject>Indans - adverse effects</subject><subject>Indans - cerebrospinal fluid</subject><subject>Indans - pharmacokinetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperidines - adverse effects</subject><subject>Piperidines - cerebrospinal fluid</subject><subject>Piperidines - pharmacokinetics</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Risperidone - adverse effects</subject><subject>Risperidone - blood</subject><subject>Risperidone - pharmacokinetics</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtv1DAUhSMEokNhzwpFSGUX8PuxnA7QgkqpeKhL43hsjTuJPdiJyvDrcZiISt2w8Ev3O-deHVfVcwheQ8j5GwAkRBwAgBCWAvEH1QJSihrCAHlYLaZyM9WPqic53wAAGaHwcXUEEYOMcbioflxtdOq1iVsf7OBNrcO6_qqdHfb1Mmebc2_DkOvo6lUMZkypPOvluvfB5yHpwccwFb_4vLPJr2Owfy3elsvO_vbd0-qR0122z-bzuPr-_t231Xlz8fnsw2p50RjKBWw0aSEVTlInsBNUIyK4scjglnNCiZSOYwQpErhtpSS2hU5jBpjARhpMDD6uXh18dyn-HG0eVO-zsV2ng41jVggSRAliBXx5D7yJYwplNoUwlUQwAQoEDpBJMedkndol3-u0VxCoKXp1P_oieTH7jm1v13eCOesCnMyAzkZ3LulgfL7jCOWcEVI4cuBuYzfYlLfdeGuT2ljdDZvSFwBS-jYIAAzKBpqy4GRPZ5nv7P6_86qPq6tzylHRNQdd-U_7659Op61iHHOqri_PFLiWp584OVWX-A_1fbfs</recordid><startdate>200302</startdate><enddate>200302</enddate><creator>Zhao, Qinying</creator><creator>Xie, Charles</creator><creator>Pesco-Koplowitz, Luana</creator><creator>Jia, Xinwei</creator><creator>Parier, Jean-Loup</creator><general>Blackwell Publishing Ltd</general><general>SAGE Publications</general><general>Sage Science</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7T2</scope><scope>7U2</scope><scope>C1K</scope></search><sort><creationdate>200302</creationdate><title>Pharmacokinetic and Safety Assessments of Concurrent Administration of Risperidone and Donepezil</title><author>Zhao, Qinying ; Xie, Charles ; Pesco-Koplowitz, Luana ; Jia, Xinwei ; Parier, Jean-Loup</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5781-a4b158f95f83f85a2487ce2c3b7745499f73215283bb994eb1fa360683c9c34c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Area Under Curve</topic><topic>Biological and medical sciences</topic><topic>Biological Availability</topic><topic>Cross-Over Studies</topic><topic>Donepezil</topic><topic>Drug Interactions</topic><topic>Humans</topic><topic>Indans - adverse effects</topic><topic>Indans - cerebrospinal fluid</topic><topic>Indans - pharmacokinetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperidines - adverse effects</topic><topic>Piperidines - cerebrospinal fluid</topic><topic>Piperidines - pharmacokinetics</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Risperidone - adverse effects</topic><topic>Risperidone - blood</topic><topic>Risperidone - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Qinying</creatorcontrib><creatorcontrib>Xie, Charles</creatorcontrib><creatorcontrib>Pesco-Koplowitz, Luana</creatorcontrib><creatorcontrib>Jia, Xinwei</creatorcontrib><creatorcontrib>Parier, Jean-Loup</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Qinying</au><au>Xie, Charles</au><au>Pesco-Koplowitz, Luana</au><au>Jia, Xinwei</au><au>Parier, Jean-Loup</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetic and Safety Assessments of Concurrent Administration of Risperidone and Donepezil</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>2003-02</date><risdate>2003</risdate><volume>43</volume><issue>2</issue><spage>180</spage><epage>186</epage><pages>180-186</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><coden>JCPCBR</coden><abstract>Treatment of Alzheimer's disease sometimes uses combinations of drugs because dementia is frequently associated with behavioral symptoms. Risperidone and donepezil are both metabolized through cytochrome P450 2D6 and 3A4, raising the possibility of drug interactions with combination therapy. The objective of this study was to determine whether significant drug interactions occur with concomitant administration of donepezil and risperidone. In an open‐label, three‐way crossover study, 24 healthy men were randomly assigned to receive 0.5 mg of risperidone twice daily, 5 mg of donepezil once daily, or both drugs for 14 consecutive days, followed by a 21‐day washout period. The treatment ratios of AUC and associated 90% confidence intervals (CIs) for risperidone active moiety, defined as risperidone plus 9‐hydroxyrisperidone (ratio = 110.2%; 90% CI = 103.7–117.2), and for donepezil (ratio = 97.1%; 90% CI = 90.0–103.6) were within the 80% to 125% of bioequivalence range. The treatment ratios of Cmax and associated 90% CIs for risperidone active moiety (ratio = 114.6%; 90% CI = 107.0–122.8) and for donepezil (ratio = 96.1%; 90% CI = 90.0–102.6) were also within the bioequivalence range. Therefore, no significant pharmacokinetic differences occurred in either risperidone active moiety or donepezil when given alone or in combination. Adverse events (predominantly headache, nervousness, and somnolence) were minor and comparable for all treatment groups. The results indicate that no clinically meaningful drug interactions occurred between risperidone 1 mg daily and donepezil 5 mg daily at steady state, and therefore no dosage adjustment is required when both drugs are combined with the dosage regimen studied. Additional investigations are warranted to determine the potential for interactions in elderly patients with dementia who may eliminate risperidone and donepezil more slowly and thus be more vulnerable to clinical drug interactions than the young healthy subjects examined in this study.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>12616671</pmid><doi>10.1177/0091270002239827</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0091-2700
ispartof Journal of clinical pharmacology, 2003-02, Vol.43 (2), p.180-186
issn 0091-2700
1552-4604
language eng
recordid cdi_proquest_miscellaneous_21425426
source MEDLINE; Access via Wiley Online Library
subjects Adult
Area Under Curve
Biological and medical sciences
Biological Availability
Cross-Over Studies
Donepezil
Drug Interactions
Humans
Indans - adverse effects
Indans - cerebrospinal fluid
Indans - pharmacokinetics
Male
Medical sciences
Neuropharmacology
Pharmacology. Drug treatments
Piperidines - adverse effects
Piperidines - cerebrospinal fluid
Piperidines - pharmacokinetics
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Risperidone - adverse effects
Risperidone - blood
Risperidone - pharmacokinetics
title Pharmacokinetic and Safety Assessments of Concurrent Administration of Risperidone and Donepezil
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T02%3A37%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetic%20and%20Safety%20Assessments%20of%20Concurrent%20Administration%20of%20Risperidone%20and%20Donepezil&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Zhao,%20Qinying&rft.date=2003-02&rft.volume=43&rft.issue=2&rft.spage=180&rft.epage=186&rft.pages=180-186&rft.issn=0091-2700&rft.eissn=1552-4604&rft.coden=JCPCBR&rft_id=info:doi/10.1177/0091270002239827&rft_dat=%3Cproquest_cross%3E21425426%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=235948680&rft_id=info:pmid/12616671&rfr_iscdi=true